Drugs / tasadenoturev
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07444606 | Aug 2026 → Jan 2027 expected | melanoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03896568 | Feb 2019 → Sep 2027 expected | anaplastic astrocytoma, gliosarcoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03178032 | May 2017 → Jan 2021 | brain stem glioma | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 1 | NCT02197169 | Sep 2014 → Mar 2018 | malignant glioma | DNAtrix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00805376 | Feb 2009 → Feb 2015 | brain cancer | DNAtrix, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07424092 | May 2026 → May 2029 expected | embryonal neoplasm, ependymoma, high grade astrocytic tumor | Clinica Universidad de Navarra, Universidad de Navarra | Recruiting | No outcome recorded |
| Phase 2 | NCT05009992 | Oct 2021 → Dec 2027 expected | diffuse midline glioma, H3 K27M-mutant, grade III glioma | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2 | NCT02798406 | Oct 2016 → Mar 2021 | gliosarcoma | DNAtrix, Inc. | Completed | Mixed |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tasadenoturev | “Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus.” PMID 29432077 ↗ Feb 2018 |
| Known as | Delta-24-RGD | “Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus.” PMID 29432077 ↗ Feb 2018 |
| Known as | DNX-2401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444606 ↗ |
| Route | Other | “DNX-2401 is given by a surgical procedure where a neurosurgeon precisely injects DNX-2401 through a catheter (small tube) that is inserted into your brain tumor.” NCT00805376 ↗ |